Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Mar 17:15:17588359231156393.
doi: 10.1177/17588359231156393. eCollection 2023.

Time for a lead-time definition? Author response to 'Why the length of recurrence free survival or "lead-times" can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis'

Karen-Lise Garm Spindler  1 , Louise Bach Callesen  2 , Dirk Arnold  3
Affiliations
Comment

Time for a lead-time definition? Author response to 'Why the length of recurrence free survival or "lead-times" can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis'

Karen-Lise Garm Spindler et al. Ther Adv Med Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Schematic overview of definition of lead-time in the curative (a) and palliative (b) setting. Clinical lead-time can be defined as the time between blood-based detected and clinical-detected recurrence/progression. The biological lead-time can only be defined if scans and blood samples are done at the same time. MRD, minimal residual disease; SOC, standard of care.
See this image and copyright information in PMC

Comment on

References

    1. Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis. Ther Adv Med Oncol 2022; 14: 1–18. - PMC - PubMed
    1. Faulkner LG, Howells LM, Pepper C, et al. The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis. Br J Cancer Epub ahead of print 2022. DOI: 10.1038/s41416-022-02017-9. - DOI - PMC - PubMed
    1. Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 2015; 7: 302ra133. - PubMed
    1. Reinert T, Schøler L V., Thomsen R, et al. . Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 2016; 65: 625–634. - PubMed
    1. Callesen LB, Hamfjord J, Boysen AK, et al. Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis. Br J Cancer 2022; 127: 500–513. - PMC - PubMed

LinkOut - more resources